PROTEOMIC BIOMARKER PROFILING OF CERVICAL SWABS

宫颈拭子的蛋白质组生物标志物分析

• 批准号: 8361413
• 负责人: Janet S. Rader
• 金额: $ 0.81万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-01-01 至 2011-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8361413
• 关键词: Aryl Hydrocarbon Receptor; Biological Markers; Cell Cycle; Cells; Cervical; Cervical Cancer Screening; Cervix Uteri; Collection; DNA damage checkpoint; Data Set; Development; Epithelial; Funding; Genes; Genomics; Grant; Liquid substance; Malignant neoplasm of cervix uteri; Mass Spectrum Analysis; Methods; Microarray Analysis; Modeling; Molecular; National Center for Research Resources; Nucleic Acids; Outcome; Pathway interactions; Patients; Pattern; Principal Investigator; Proteins; Proteomics; Protocols documentation; Receptor Signaling; Regulation; Research; Research Infrastructure; Resources; Sampling; Screening procedure; Signal Transduction; Source; Specimen; Spottings; Swab; Tissues; Two-Dimensional Gel Electrophoresis; United States National Institutes of Health; biomedical resource; cDNA Arrays; cancer cell; clinical practice; cost; endoplasmic reticulum stress; interest; neoplastic; two-dimensional

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The Rader lab is interested in using integrated proteomic and genomic screening to find potential biomarkers for cervical cancer. Cervical cancer screening is ideally suited for the development of biomarkers due to the ease of tissue acquisition and the well- established histological transitions. Furthermore, cell and biologic fluid obtained from cervix samples undergo specific molecular changes that can be profiled and models constructed that may predict outcome. A patient screening protein and nucleic acid collection protocol was established using standard spatulas and cytobrushes already used in clinical practice. RNAlater was used to collect the samples followed by proteomic methods to identify biomarkers/proteins that were differentially expressed in normal cervical epithelial versus cervical cancer cells. Three hundred ninety spots were identified via two-dimensional difference gel electrophoresis (2-D DIGE) that were expressed at either higher or lower levels (>3-fold) in cervical cancer samples. These proteomic results were compared to the most significant genes in a cDNA microarray analysis of microdissected neoplastic cervical specimens to identify overlapping patterns of expression. The most frequent pathways represented by the combined dataset were: cell cycle: G2/M DNA damage checkpoint regulation; aryl hydrocarbon receptor signaling; p53 signaling; cell cycle: G1/S checkpoint regulation; and the endoplasmic reticulum stress pathway.

该副本是利用资源的众多研究子项目之一 由NIH/NCRR资助的中心赠款提供。对该子弹的主要支持 而且，副投影的主要研究员可能是其他来源提供的 包括其他NIH来源。 列出的总费用可能 代表subproject使用的中心基础架构的估计量， NCRR赠款不直接向子弹或副本人员提供的直接资金。 Rader Lab有兴趣使用集成的蛋白质组学和基因组筛选来找到 宫颈癌的潜在生物标志物。宫颈癌筛查非常适合 由于易于组织的易于性和良好的发展，生物标志物的发展 建立的组织学转变。此外，从 子宫颈样品会经历特定的分子变化，可以构造并模型 构建可以预测结果。患者筛查蛋白和核酸 已经使用标准的Spatulas和cytobrushes建立了收集协议 用于临床实践。 rnalater用于收集样品，然后是蛋白质组学 鉴定在正常情况下差异表达的生物标志物/蛋白质的方法 宫颈上皮与宫颈癌细胞。 三百九十个景点是 通过二维差异凝胶电泳（2-D DIGE）确定 在宫颈癌样品中以较高或较低的水平（> 3倍）表达。这些 将蛋白质组学结果与cDNA微阵列中最重要的基因进行比较 分析微解剖的肿瘤性宫颈标本以识别重叠模式 表达。组合数据集表示的最常见的途径 为：细胞周期：G2/M DNA损伤检查点调节；芳基烃受体 信号传导； p53信号传导；细胞周期：G1/S检查点调节；和内质 网状应力途径。